Trials / Completed
CompletedNCT02678598
A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,555 (actual)
- Sponsor
- Astellas Pharma China, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy of intravenous micafungin for the empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy patients with invasive fungal infections caused by Candida sp. or Aspergillus sp. (fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Micafungin | Intravenous |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2016-02-10
- Last updated
- 2016-02-10
Locations
17 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02678598. Inclusion in this directory is not an endorsement.